The European Randomized study of Screening for Prostate Cancer (ERSPC) reported that prostate-specific antigen (PSA) screening decreased prostate cancer mortality, but that it increased substantial unnecessary biopsies, which resulted in undesirable complications such as fever, haematuria and haematospermia [23, 24]. The gene discussed is KLK3; the disease is prostate cancer.